Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo

• Ngā kaituhi matua: Zheng Wang (Author), Yu Liu (Author), Yunxia Xu (Author), Lin Lu (Author), Zhen Zhu (Author), Baojie Lv (Author), Xin Fang (Author), Yao Tang (Author), Jinhua Wang (Author), Yu Cheng (Author), Ying Hu (Author), Junwen Lou (Author), Peican Wu (Author), Chendan Liu (Author), Yanjun Liu (Author), Xin Zeng (Author), Qing Xu (Author)
• Hōputu: Pukapuka
• I whakaputaina: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Currently approved human epidermal growth factor receptor 2 (HER2)-targeted antibody therapies are largely derived from trastuzumab, including trastuzumab-chemotherapy combinations, fixed-dose trastuzumab-pertuzumab combinations, and trastuzumab antibody-drug conjugates. To expand the options, bispe...